BackInnate Pharma Overview

Innate Pharma Current Cash

Track Innate Pharma's current cash ($28M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$28.08M
↓ 57.71% YoYΔ $-38.32M vs prior year quarter

Peer trimmed avg / median

Loading

Innate Pharma Current Cash History

Loading

Innate Pharma vs. peers: Current Cash Comparison

Loading

Innate Pharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Innate Pharma (IPHA) FAQ

Innate Pharma (IPHA) currently reports a current cash of $28M as of December 2025. That compares with $66M in the prior-year period — down 57.7% year over year. Use the charts on this page to explore Innate Pharma's current cash history and peer comparisons.

Innate Pharma's current cash decreased from $66M to $28M — a 57.7% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Innate Pharma reported $28M in current cash as of December 2025. That compares with $66M in the prior-year period — down 57.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $28M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Innate Pharma, and consider following IPHA for alerts when major investors trade the stock.

Innate Pharma is classified in the Healthcare sector. On current cash, it currently shows $28M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IPHA with unrelated industries.